Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France.

Autor:	Cadranel JD; Department of Liver and Digestive Diseases, GHPSO, Creil., Zougmoré HT; Department of Liver and Digestive Diseases, GHPSO, Creil., Efole JN; Department of Liver and Digestive Diseases, GHPSO, Creil., Hanslik B; Gastroenterology Office, Montpellier., Causse X; Department of Liver and Digestive Diseases, Orléans., Rosa I; Department of Liver and Digestive Diseases, CHI Créteil., Lemaitre C; Department of Liver and Digestive Diseases, Le Havre., Mokhtari C; Department of Virology GHPSO, Creil., Baron A; Department of Liver and Digestive Diseases, Corbeil., Thevenot T; Department of Liver and Digestive Diseases, Besançon., Medmoun M; Department of Liver and Digestive Diseases, GHPSO, Creil., Smadhi R; Department of Liver and Digestive Diseases, GHPSO, Creil., Fantognon G; Department of Liver and Digestive Diseases, GHPSO, Creil., Remy AJ; Department of Liver and Digestive Diseases, Perpignan., Macaigne G; Department of Liver and Digestive Diseases, Montfermeil., Arondel Y; Department of Liver and Digestive Diseases, Haguenau., Arpurt JP; Department of Liver and Digestive Diseases, Avignon., Bellaiche G; Department of Liver and Digestive Diseases, Aulnay-sous-bois., Bourlière M; Department of Liver and Digestive Diseases, Marseille., De Kerguenec C; Department of Liver and Digestive Diseases, Saint Denis., Heluwaert F; Department of Liver and Digestive Diseases, Annecy., Verlynde J; Department of Liver and Digestive Diseases, Dunkerque., Halfon P; Department of Internal Medicine and Infectious Diseases, Alphabio Laboratory Marseille, Marseille., Roulot D; Department of Liver and Digestive Diseases, Bobigny., Carrier P; Department of Liver and Digestive Diseases, Limoges., Loustaud-Ratti V; Department of Liver and Digestive Diseases, Limoges., Lemagoarou T; Department of Medical Information, GHPSO, Creil, France.
Jazyk:	angličtina
Zdroj:	European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2024 Jun 01; Vol. 36 (6), pp. 735-741. Date of Electronic Publication: 2024 Apr 24.
DOI:	10.1097/MEG.0000000000002707
Abstrakt:	Background: Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France. Objective: We aimed to evaluate the knowledge and practices of HGs practicing in nonacademic settings regarding HB-D. Methods: A Google form document was sent to those HGs from May to September 2021. Results: A total of 130 HGs (mean age, 45 years) have participated in this survey. Among HBsAg-positive patients, Delta infection was sought in only 89% of cases. Liver fibrosis was assessed using FibroScan in 77% of the cases and by liver biopsy in 81% of the cases. A treatment was proposed for patients with >F2 liver fibrosis in 49% of the cases regardless of transaminase levels and for all the patients by 39% of HGs. Responding HGs proposed a treatment using pegylated interferon in 50% of cases, bulevirtide in 45% of cases and a combination of pegylated interferon and bulevirtide in 40.5% of cases. Among the criteria to evaluate the treatment efficacy, a decrease or a normalization of transaminases was retained by 89% of responding HGs, a reduction of liver fibrosis score for 70% of them, an undetectable delta RNA and HBsAg for 55% of them and a 2 log 10 decline in delta viremia for 62% of the cases. Conclusion: Hepatitis Delta screening was not systematically performed in HBsAg-positive patients despite the probable awareness and knowledge of the few responders who were able to prescribe treatments of hepatitis delta. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu